Theratechnologies Investor Relations Material

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in cardiology, oncology, and women's health. The company primarily develops peptide-based therapeutics. Its product candidates include Onbrez Breezhaler, which is in Phase III clinical trial for the symptomatic relief of chronic obstructive pulmonary disease; and Theratears for Atopic Keratoconjunctivitis (MK), which is under Phase III clinical trial for the treatment of atopic keratoconjunctivitis. Theratechnologies Inc is headquartered in Montreal, Canada.